On March 20, 2025, Johnson & Johnson’s Tremfya® (guselkumab) received FDA approval for a label expansion for the treatment of Crohn’s Disease (CD). Tremfya® is the first and only interleukin (IL)-23 inhibitor offering both subcutaneous ...
A new oral weight loss medication by Eli Lilly, Orforglipron, showed promising results in a phase 2 trial published in the New England Journal of Medicine in June 2023. The highest dose of the drug resulted in approximately 15% weight loss ...
On March 7, 2025, the US Food and Drug Administration (FDA) approved Celltrion’s Omlyclo® (omalizumab-igec) as the first interchangeable biosimilar to Novartis’ Xolair® (omalizumab). Omlyclo is approved for the same indications as ...
The US Food and Drug Administration (FDA) has determined the shortage of glucagon-like peptide 1 (GLP-1) medication, semaglutide, is resolved. Semaglutide injection products have been on the FDA shortage list since 2022. The FDA ...
The 2023 United States Preventive Services Task Force (USPSTF) recommendation for PrEP specifically cites the three medications currently approved by the FDA for use as PrEP. Therefore, it is the position of The Departments, as outlined in FAQ…
